Sugammadex vs. Neostigmine for Reversal of Neuromuscular Blockade: Evidence, Outcomes, Cost, and the 2023 ASA Guideline Shift Scope and Framing This review covers the comparative efficacy, safety, clinical outcomes, cost-effectiveness, and guideline recommendations for sugammadex versus neostigmine in reversing aminosteroidal neuromuscular blockade (rocuronium/vecuronium) in adults. It integrates the 2023 ASA…
THE EVIDENCE
What each source contributes, and how strong it is
Study design first — a cohort and a randomised trial do not carry the same weight.
Design
Year
Journal
What it found
Guideline
2023
Anesthesiology
The 2023 ASA practice guideline directs both how neuromuscular blockade is monitored
Meta-analysis
2020
Journal of clinical anesthesia
Routine sugammadex is the cheaper choice once operating-room time is valued above
Randomised trial
2020
British journal of anaesthesia
In patients over 70 having surgery of three hours or more, sugammadex cut residual
Cohort
2020
Anesthesiology
Across 45,712 matched inpatients, sugammadex was associated with a 30% lower risk of
Review
2019
BMC anesthesiology
Sugammadex can fail in myasthenia gravis — 800 mg left the train-of-four ratio stuck
Meta-analysis
2023
BMC anesthesiology
Pooled against neostigmine, sugammadex lowered pneumonia, atelectasis, non-invasive
6 resolved citations behind this deck; every point above traces to one of them.
WHERE THE GUIDANCE SITS
What the guidelines and pooled evidence say
3 findings, each on the slide that follows.
Anesthesiology 2023
The 2023 ASA practice guideline directs both how neuromuscular blockade is monitored
The 2023 ASA practice guideline directs both how neuromuscular blockade is monitored and how it is antagonised, with the explicit aim of reducing…
Journal of clinical anesthesia 2020
Routine sugammadex is the cheaper choice once operating-room time is valued above
Routine sugammadex is the cheaper choice once operating-room time is valued above about $8.60 per minute; on drug and nausea costs alone the…
BMC anesthesiology 2023
Pooled against neostigmine, sugammadex lowered pneumonia, atelectasis, non-invasive
Pooled against neostigmine, sugammadex lowered pneumonia, atelectasis, non-invasive ventilation and reintubation
WHERE THE GUIDANCE SITS
The 2023 ASA practice guideline directs both how neuromuscular blockade is monitored
Guideline · Anesthesiology
The 2023 ASA practice guideline directs both how neuromuscular blockade is monitored and how it is antagonised, with the explicit aim of reducing residual blockade after general anaesthesia.
2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade, Anesthesiology 2023 · PMID 36520073
WHERE THE GUIDANCE SITS
Routine sugammadex is the cheaper choice once operating-room time is valued above
Meta-analysis · Journal of clinical anesthesia
Routine sugammadex is the cheaper choice once operating-room time is valued above about $8.60 per minute; on drug and nausea costs alone the economics do not support it.
Sugammadex Versus Neostigmine for Routine Reversal of Rocuronium Block in Adult Patients: A Cost Analysis, Journal of clinical anesthesia 2020 · PMID 32980763
WHERE THE GUIDANCE SITS
Pooled against neostigmine, sugammadex lowered pneumonia, atelectasis, non-invasive
Meta-analysis · BMC anesthesiology
Pooled against neostigmine, sugammadex lowered pneumonia, atelectasis, non-invasive ventilation and reintubation, while the rate of desaturation was no different between the two.
Postoperative Pulmonary Complications After Sugammadex Reversal of Neuromuscular Blockade: A Systematic Review and Meta-Analysis With Trial Sequential Analysis, BMC anesthesiology 2023 · PMID 37081384
WHAT THE TRIALS FOUND
In patients over 70 having surgery of three hours or more, sugammadex cut residual
Randomised trial · British journal of anaesthesia
In patients over 70 having surgery of three hours or more, sugammadex cut residual paralysis in recovery from 49% to 10% versus neostigmine, without a significant difference in postoperative pulmonary complications.
Randomised Controlled Trial of Sugammadex or Neostigmine for Reversal of Neuromuscular Block on the Incidence of Pulmonary Complications in Older Adults Undergoing Prolonged Surgery, British journal of anaesthesia 2020 · PMID 32139135
THE NUMBERS
Sugammadex nearly eliminated residual paralysis
Patients over 70 having surgery of three hours or more.
Residual block fell from 49% to 10%; the pulmonary complication difference did not reach significance.
Randomised Controlled Trial of Sugammadex or Neostigmine for Reversal of Neuromuscular Block on the Incidence of Pulmonary Complications in Older Adults Undergoing Prolonged Surgery, British journal of anaesthesia 2020 · PMID 32139135
IN PRACTICE
What the cohorts and reviews add
2 findings, each on the slide that follows.
Anesthesiology 2020
Across 45,712 matched inpatients, sugammadex was associated with a 30% lower risk of
Across 45,712 matched inpatients, sugammadex was associated with a 30% lower risk of major pulmonary complications, a 47% lower risk of pneumonia and…
BMC anesthesiology 2019
Sugammadex can fail in myasthenia gravis — 800 mg left the train-of-four ratio stuck
Sugammadex can fail in myasthenia gravis — 800 mg left the train-of-four ratio stuck at 60% until neostigmine was given — so monitor the block rather…
IN PRACTICE
Across 45,712 matched inpatients, sugammadex was associated with a 30% lower risk of
Cohort · Anesthesiology
Across 45,712 matched inpatients, sugammadex was associated with a 30% lower risk of major pulmonary complications, a 47% lower risk of pneumonia and a 55% lower risk of respiratory failure than neostigmine.
Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis, Anesthesiology 2020 · PMID 32282427
THE NUMBERS
STRONGER: lower pulmonary complications across 45,712 matched patients
Adjusted odds versus neostigmine.
A 30% to 55% reduction across three separate respiratory outcomes in matched observational data.
Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis, Anesthesiology 2020 · PMID 32282427
IN PRACTICE
Sugammadex can fail in myasthenia gravis — 800 mg left the train-of-four ratio stuck
Review · BMC anesthesiology
Sugammadex can fail in myasthenia gravis — 800 mg left the train-of-four ratio stuck at 60% until neostigmine was given — so monitor the block rather than assuming reversal.
Failure of Reversion of Neuromuscular Block With Sugammadex in Patient With Myasthenia Gravis: Case Report and Brief Review of Literature, BMC anesthesiology 2019 · PMID 31421671
THE NUMBERS
A single-centre switch showed no such difference
10,491 cases before and after replacing neostigmine with sugammadex.
Confidence interval crossed 1 — the observational signal is not universal, which is worth saying out loud.
IN THE ROOM
What this changes about the next case
Colour is the strength of the evidence behind each step, not the urgency.
1
1
The 2023 ASA practice guideline directs both how neuromuscular blockade is monitored and how it is antagonised, with the explicit aim of reducing residual blockade after general anaesthesia.
2
2
Routine sugammadex is the cheaper choice once operating-room time is valued above about $8.60 per minute; on drug and nausea costs alone the economics do not support it.
3
3
Pooled against neostigmine, sugammadex lowered pneumonia, atelectasis, non-invasive ventilation and reintubation, while the rate of desaturation was no different between the two.
4
4
In patients over 70 having surgery of three hours or more, sugammadex cut residual paralysis in recovery from 49% to 10% versus neostigmine, without a significant difference in postoperative pulmonary complications.
5
5
Across 45,712 matched inpatients, sugammadex was associated with a 30% lower risk of major pulmonary complications, a 47% lower risk of pneumonia and a 55% lower risk of respiratory failure than neostigmine.
The oral-boards stem on the next slide puts these into one scenario.
KEY TAKEAWAYS
What to carry into the next case
The 2023 ASA practice guideline directs both how neuromuscular blockade is monitored
Anesthesiology 2023
Routine sugammadex is the cheaper choice once operating-room time is valued above
Journal of clinical anesthesia 2020
In patients over 70 having surgery of three hours or more, sugammadex cut residual
British journal of anaesthesia 2020
Across 45,712 matched inpatients, sugammadex was associated with a 30% lower risk of
Anesthesiology 2020
The 2023 ASA practice guideline directs both how neuromuscular blockade is monitored
Questions I'll ask you in the room
Walk me through your setup for this before we start.
What are you watching on the monitor that would tell you this is going wrong?
What is your first move if it does?
What would you want ready in the room before induction?
Oral boards stem
A 66-year-old is at the end of a two-hour laparoscopic colectomy. The train-of-four shows two twitches with fade, the surgeon is closing, and the resident asks which reversal agent to draw up and at what dose.
Board questions
1. What two aspects of neuromuscular blockade management does the 2023 ASA practice guideline address, and what is its explicitly stated aim?
Show answer
It directs both how neuromuscular blockade is monitored and how it is antagonised, with the explicit aim of reducing residual blockade after general anaesthesia.
Monitoring and reversal are handled in one guideline for a reason — the shared goal is keeping residual blockade out of recovery.
2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade, Anesthesiology 2023 · PMID 36520073
2. In the randomised trial of patients over 70 having surgery of three hours or more, what happened to the rate of residual paralysis in recovery with sugammadex compared with neostigmine, and what happened to postoperative pulmonary complications?
Show answer
Residual paralysis in recovery fell from 49% with neostigmine to 10% with sugammadex, but there was no significant difference in postoperative pulmonary complications between the two groups.
Sugammadex clearly fixed the twitch in this trial, and that still did not produce a significant difference in pulmonary complications.
Randomised Controlled Trial of Sugammadex or Neostigmine for Reversal of Neuromuscular Block on the Incidence of Pulmonary Complications in Older Adults Undergoing Prolonged Surgery, British journal of anaesthesia 2020 · PMID 32139135
3. A patient with myasthenia gravis has received rocuronium. What does the reported case experience show can happen after a large dose of sugammadex, and what practical step does it argue for?
Show answer
Sugammadex can fail in myasthenia gravis: in a reported case, 800 mg left the train-of-four ratio stuck at 60% until neostigmine was given. The practical step is to monitor the block rather than assuming that a dose of sugammadex has reversed it.
One reported failure is enough to change your habit here: in myasthenia gravis, confirm reversal on the monitor instead of assuming the dose worked.
Failure of Reversion of Neuromuscular Block With Sugammadex in Patient With Myasthenia Gravis: Case Report and Brief Review of Literature, BMC anesthesiology 2019 · PMID 31421671
4. A resident cites the STRONGER analysis of 45,712 matched inpatients as proof that sugammadex prevents postoperative pneumonia. State what that analysis actually reported and what its design does not let you claim.
Show answer
It reported that sugammadex was associated with a 30% lower risk of major pulmonary complications, a 47% lower risk of pneumonia and a 55% lower risk of respiratory failure than neostigmine. Those are associations from a matched cohort, not results of a randomised comparison, so they do not establish that sugammadex prevents these complications.
Keep the word 'associated with' — a matched cohort of 45,712 patients is still an association, however large the numbers look.
Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis, Anesthesiology 2020 · PMID 32282427
The bottom lineThe 2023 ASA practice guideline directs both how neuromuscular blockade is monitored
Sources
[1] 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade, Anesthesiology 2023 · PMID 36520073 open
[2] Sugammadex Versus Neostigmine for Routine Reversal of Rocuronium Block in Adult Patients: A Cost Analysis, Journal of clinical anesthesia 2020 · PMID 32980763 open
[3] Randomised Controlled Trial of Sugammadex or Neostigmine for Reversal of Neuromuscular Block on the Incidence of Pulmonary Complications in Older Adults Undergoing Prolonged Surgery, British journal of anaesthesia 2020 · PMID 32139135 open
[4] Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis, Anesthesiology 2020 · PMID 32282427 open
[5] Failure of Reversion of Neuromuscular Block With Sugammadex in Patient With Myasthenia Gravis: Case Report and Brief Review of Literature, BMC anesthesiology 2019 · PMID 31421671 open
[6] Postoperative Pulmonary Complications After Sugammadex Reversal of Neuromuscular Blockade: A Systematic Review and Meta-Analysis With Trial Sequential Analysis, BMC anesthesiology 2023 · PMID 37081384 open